| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
|
N Engl J Med
|
2011
|
28.99
|
|
2
|
Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
|
Circulation
|
2012
|
4.10
|
|
3
|
Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.
|
Lancet Neurol
|
2012
|
2.77
|
|
4
|
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
|
Circulation
|
2015
|
2.57
|
|
5
|
Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study.
|
Am Heart J
|
2010
|
2.46
|
|
6
|
Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
|
Lancet
|
2015
|
1.81
|
|
7
|
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
|
Circulation
|
2014
|
1.54
|
|
8
|
Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial.
|
Eur Heart J
|
2014
|
1.50
|
|
9
|
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor.
|
Nat Rev Drug Discov
|
2010
|
1.33
|
|
10
|
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.
|
J Am Heart Assoc
|
2013
|
1.26
|
|
11
|
Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial.
|
J Am Coll Cardiol
|
2013
|
1.23
|
|
12
|
Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
|
J Am Coll Cardiol
|
2013
|
1.20
|
|
13
|
On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
|
Circulation
|
2016
|
1.09
|
|
14
|
New oral anticoagulants may be particularly useful for asian stroke patients.
|
J Stroke
|
2014
|
1.00
|
|
15
|
Efficacy and safety of rivaroxaban in patients with heart failure and nonvalvular atrial fibrillation: insights from ROCKET AF.
|
Circ Heart Fail
|
2013
|
0.93
|
|
16
|
Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
|
Eur Heart J
|
2014
|
0.92
|
|
17
|
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
|
J Clin Pharmacol
|
2014
|
0.91
|
|
18
|
XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation.
|
Vasc Health Risk Manag
|
2014
|
0.91
|
|
19
|
A systems approach to designing effective clinical trials using simulations.
|
Circulation
|
2012
|
0.89
|
|
20
|
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trial.
|
Ann Intern Med
|
2013
|
0.86
|
|
21
|
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trial.
|
J Am Heart Assoc
|
2015
|
0.85
|
|
22
|
New antithrombotic agents--insights from clinical trials.
|
Nat Rev Cardiol
|
2010
|
0.84
|
|
23
|
Rivaroxaban -- an oral, direct Factor Xa inhibitor: lessons from a broad clinical study programme.
|
Eur J Haematol
|
2009
|
0.80
|
|
24
|
Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.
|
Heart Rhythm
|
2014
|
0.80
|
|
25
|
Use of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Valvular Heart Lesions.
|
J Am Heart Assoc
|
2016
|
0.77
|
|
26
|
Secondary stroke prevention strategies for the oldest patients: possibilities and challenges.
|
Drugs Aging
|
2009
|
0.77
|
|
27
|
Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.
|
Adv Ther
|
2015
|
0.76
|
|
28
|
Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
|
J Am Heart Assoc
|
2016
|
0.75
|
|
29
|
Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
|
Am J Cardiovasc Drugs
|
2016
|
0.75
|
|
30
|
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
|
Am Heart J
|
2015
|
0.75
|
|
31
|
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban.
|
Heart
|
2016
|
0.75
|